NeuroSense Therapeutics (NRSN) Liabilities and Shareholders Equity (2020 - 2025)

NeuroSense Therapeutics has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 77.53% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (down 6.5% YoY) and the FY2025 annual result came in at $1.0 million, down 77.53% from the prior year.
• Liabilities and Shareholders Equity retreated to $1.0 million in Q4 2025 per NRSN's latest filing, from $1.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $14.4 million in Q1 2022 and troughed at $984000.0 in Q3 2024.
• A 5-year average of $5.8 million and a median of $5.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity jumped 1367.39% in 2021, then plunged 81.73% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $11.4 million in 2021, then tumbled by 32.49% to $7.7 million in 2022, then sank by 58.73% to $3.2 million in 2023, then jumped by 43.64% to $4.6 million in 2024, then plunged by 77.53% to $1.0 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.0 million, $1.7 million, and $4.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.